scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Core Viewpoint - scPharmaceuticals reported significant revenue growth for FUROSCIX in 2024, driven by increased demand and FDA approval for a new indication in chronic kidney disease [1][4][9]. Financial Performance - Fourth quarter 2024 net FUROSCIX revenue was $12.2 million, a 99$6.1 million in Q4 2023 [4][5]. - Full year 2024 revenue reached $36.3 million, up 167$13.6 million in 2023 [4][5]. - Cost of product revenues for Q4 2024 was $4.0 million, compared to$1.8 million in Q4 2023 [5]. - R&D expenses for Q4 2024 were $3.2 million, slightly down from$3.3 million in Q4 2023 [7]. - SG&A expenses increased to $21.4 million in Q4 2024 from$16.2 million in Q4 2023 [8]. - The company reported a net loss of $18.8 million for Q4 2024, compared to a net loss of$13.8 million in Q4 2023 [9]. Product Development and Market Expansion - The FDA approved FUROSCIX for treating edema in chronic kidney disease on March 6, 2025, with a formal launch anticipated in April 2025 [5][6]. - The company filled approximately 13,300 FUROSCIX doses in Q4 2024, a 23% increase from Q3 2024 [5]. - scPharmaceuticals is advancing the 80mg/1mL FUROSCIX Autoinjector program, targeting a supplemental New Drug Application submission mid-year 2025 [5]. Cash Position and Shareholder Information - As of December 31, 2024, cash and cash equivalents were $75.7 million, slightly down from$76.0 million at the end of 2023 [9][25]. - Total shares outstanding as of December 31, 2024, were 50,095,689 [10].